Table 2.

Published case reports of treatment with ALK inhibitor in CRC patients harboring ALK gene alternation

First author (year)	Age/gender	Clinical presentation	Fusion partner	First method of detecting ALK	Treatment and response	Follow-up**
Amatu (2015) [9]	53/F	Right side CRC, stage IV with brain, thoracic lymph node and liver metastasis	CAD-ALK	IHC	Entrectinib: PR for 4.5 months
Yakirevich (2016) [5]	87/F	A-colon (cecum), lung metastasis, PD with peritoneal and umbilical metastasis	STRN-ALK	NGS	FOLFOX6: PR; FOLFIRI: SD at least; ceritinib SD for 9 months	KRAS G13D (post ceritinib)
Gambacorti-Passerini (2018) [8]	N/A	Mucinous type CRC	N/A	FaISH	Crizotinib: response duration 25 months
Hsiao (2021)*	56/M	A-colon, stage IV with lung, liver, and peritoneal metastasis	EML4-ALK	NGS	Anti-EGFR with FOLFOX: PR for 3 months; anti-VEGF with FOLFOXIRI: PD; alectinib: PR for 8 months; ceritinib and brigatinib: PD	KRAS Q61H (post alectinib)

PR, partial response; SD, stable disease; PD, progressive disease; A-colon, ascending colon; IHC, immunohistochemistry; NGS, next-generation sequencing; FISH, fluorescence in situ hybridization; N/A, not available.

^*This report.

^**Suspicious emerging resistant mutation after ALK inhibitor.